FDA offers Acurx path to NDA with single Phase 3 trial for CDI drug

August 3, 2026 8:00 AM

Acurx Pharmaceuticals (NASDAQ: ACXP) said the FDA has provided guidance indicating it is open to reviewing a New Drug Application ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found